Nick Guldemond on cancer medication expenditure
Nick Guldemond, Professor of Integrated Care and Technology, CEO and founder of Medical Field Lab, posted on LinkedIn:
“As expenditure on cancer medication in the Netherlands reaches record levels, organizations call for more research to ensure the drugs are used sustainably and for EU member states to keep pace with established plans to ensure their citizens don’t get left behind. In 2012, expenditure on cancer medication was around a quarter of the total expenditure on medicines, which increased to over half by 2021, according to the Netherlands Comprehensive Cancer Organisation (IKNL). The IKNL found that the Netherlands spent approximately €10 billion over the past ten years on oncolytics. While such drugs can extend the life of some cancer patients, not all of them benefit.
The IKNL said its findings highlight a need to identify better which patients benefit the most from drugs so that they can be used more targeted in the future. The IKNL said increasing oncolytic’s costs puts pressure on hospitals’ budgets, so they may have to reduce their services to treat other conditions. Governments have to make trade-offs between how much the burden of a disease can be reduced and how much its citizens are willing to pay for this aid.”
For more information click here.
Source: Nick Guldemond/LinkedIn
-
12:46 30/11/23 | BlogJohanna Joyce: the Flashlight method
-
12:31 30/11/23 | InsightJeff Ryckman: Omitting RT in bulky early-stage cHL
-
07:45 30/11/23 | BlogAaron Goodman: Hemoglobin Dissociation Curve! Good stuff
-
12:31 30/11Jeff Ryckman: Omitting RT in bulky early-stage cHL
-
17:28 29/11JeeSuk Chang: A multi-center trial - great efforts from the KROG team
-
17:00 29/11Maite Bourlon: Access to novel drugs for metastatic renal cell carcinoma is an unmet need in the Mexican population
-
23:17 28/11Manni Mohyuddin: Current trials must have observation/surveillance as control arm
-
23:04 28/11Juan P. Alderuccio: Our approach to secondary CNS involvement by aggressive lymphomas
-
17:43 28/11Michele Carbone: The world is full of good, honest, nice people
-
17:24 28/11Jessica Clerc: Celebrating 90 Years of Excellence and Dedication in Cancer Care!
-
17:44 25/11Carlos Pedraz: Congratulations, Dr. Rafael Rosell for the very well deserved 2023 ISLB Lifetime Achievement Award
-
17:10 25/11100 Influential Celebrities in Oncology: The 2023 Edition – Part 4
-
13:34 24/11"Bald for a Cause" initiative - UWC Dilijan College
-
17:34 28/11The International Association of Cancer Registries annual conference - IARC
-
18:05 26/11Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
17:58 26/11Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
16:47 16/11How social determinants can influence a patient’s ability to stay in treatment - ASCO
-
13:22 16/11SIOP Europe Student Summer School for Paediatric Oncology
-
17:25 29/11NIH Director’s Early Independence Award supports junior scientists to launch independent careers - National Cancer Institute
-
17:07 29/11Santhosh Kumar Devadas: I’m starting a new position as a Professor of Medical Oncology and Chief of Bone Marrow Transplant at Ramaiah Memorial Hospital and Ramaiah Medical College
-
16:48 27/11CRCHD seeks motivated scientists to serve as Program Directors - NCI Disparities
-
16:25 27/11Luisa Basset completed a fruitful nine-year tenure on the CCI board of trustees - Childhood Cancer International
-
18:14 26/11Tristan Knight: Attention hematology / oncology and pediatric hematology / oncology fellows